We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

Learn more about how we are working to discover and develop innovative medicines that are more accessible and affordable to patients around the world.

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More

Our Commitment to Patients

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More

BeiGene News

May 30, 2023

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

Read more

May 25, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Read more

May 24, 2023

BeiGene to Present at Upcoming Investor Conferences

Read more

May 17, 2023

The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

Read more

May 6, 2023

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

Read more

May 4, 2023

BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

Read more